Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hsiu-Tzu Wang

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
The American Journal of the Medical Sciences|September 22, 2020
May-Hegglin AnomalyHsiu-Tzu Wang, Chang-Fang Chiu, Li-Yuan Bai
Journal of the Formosan Medical Association = Taiwan Yi Zhi|February 12, 2023
Circulating tumor cells positivity provides an early detection of recurrence of pancreatic cancerHsiu-Tzu Wang, Li-Yuan Bai, Ying-Tso Wang, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|May 8, 2024
Adjuvant chemotherapy for stage II and III gastric adenocarcinoma: A retrospective analysis with long-term follow-upHsiu-Tzu Wang, Chang-Fang Chiu, Horng-Ren Yang, et al.
International Journal of Clinical Oncology|December 10, 2025
Intraperitoneal nivolumab for malignant ascites in patients with advanced gastrointestinal or pancreaticobiliary tract cancerHsiu-Tzu Wang, Yung-Luen Yu, Wen-Jyi Lo, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|May 6, 2026
Response to Comment on "Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective multi-center cohort"I-Wei Ho, Chung-Pin Li, Shih-Hung Yang, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|April 12, 2026
Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective multi-center cohortI-Wei Ho, Chung-Pin Li, Shih-Hung Yang, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|May 22, 2026
Response to comment on "Considering the unmeasured impact of 5-fluorouracil dose intensity in the interpretation of optimal initial relative dose intensity of modified FOLFIRINOX"I-Wei Ho, Chung-Pin Li, Shih-Hung Yang, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
The American Journal of the Medical Sciences|September 22, 2020
May-Hegglin AnomalyHsiu-Tzu Wang, Chang-Fang Chiu, Li-Yuan Bai
Journal of the Formosan Medical Association = Taiwan Yi Zhi|February 12, 2023
Circulating tumor cells positivity provides an early detection of recurrence of pancreatic cancerHsiu-Tzu Wang, Li-Yuan Bai, Ying-Tso Wang, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|May 8, 2024
Adjuvant chemotherapy for stage II and III gastric adenocarcinoma: A retrospective analysis with long-term follow-upHsiu-Tzu Wang, Chang-Fang Chiu, Horng-Ren Yang, et al.
International Journal of Clinical Oncology|December 10, 2025
Intraperitoneal nivolumab for malignant ascites in patients with advanced gastrointestinal or pancreaticobiliary tract cancerHsiu-Tzu Wang, Yung-Luen Yu, Wen-Jyi Lo, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|May 6, 2026
Response to Comment on "Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective multi-center cohort"I-Wei Ho, Chung-Pin Li, Shih-Hung Yang, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|April 12, 2026
Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective multi-center cohortI-Wei Ho, Chung-Pin Li, Shih-Hung Yang, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|May 22, 2026
Response to comment on "Considering the unmeasured impact of 5-fluorouracil dose intensity in the interpretation of optimal initial relative dose intensity of modified FOLFIRINOX"I-Wei Ho, Chung-Pin Li, Shih-Hung Yang, et al.
Pageof 1